Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$32.52 +2.00%

+$0.69 today

Market cap
$6.73B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.73M

Average 1.84M

Returns on capital

Immunovant, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-59.3%

avg 976.1%

ROIC

-62.5%

avg 976.5%

ROA

-52.8%

avg -13460.1%

Analysis

ROA is currently the strongest return metric at -52.8% versus its period average of -13460.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Eric Venker

Chief Executive Officer & DirectorUSD 1.15M39257.07K0.13%

Melanie Gloria

Chief Operating OfficerUSD 759.07K48217.06K0.11%

Jay S. Stout

Chief Technology OfficerUSD 757.68K63198.94K0.10%

Christopher Van Tuyl

Chief Legal Officer & Corporate SecretaryUSD 757.09K51175.22K0.09%

Tiago Girao

Chief Financial OfficerUSD 691.21K47234.19K0.11%

Frank Torti

Executive Chairperson of the BoardUSD 92.5K4788.33K0.04%

Becky Merlina

Senior VP & Global Head of Quality————

Christine Blodgett

Senior Vice President of Human Resources————

Sheetal Patel

Senior Vice President of Clinical Development————

Yan Zheng

Senior Vice President of Biostatistics, Programming & Data Management————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 28, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$350.00M

Sells

63

$16.61M

Net Transaction Value

+$333.39M

Net buying

Most Active

Stout Jay S

16 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 11, 26

Pande Atul

Direct

Sell$108K
Oct 28, 26

Girao Tiago

Direct

Sell$188.3K
Oct 21, 26

Stout Jay S

Direct

Sell$75.1K
Oct 7, 26

Stout Jay S

Direct

Sell$51.2K
Oct 7, 26

Stout Jay S

Direct

Sell$70.9K
Oct 7, 26

Van Tuyl Christopher

Direct

Sell$42.5K
Oct 7, 26

Gloria Melanie

Direct

Sell$71.8K
Oct 2, 26

Venker Eric

Direct

Sell$119.6K
Sep 23, 26

Van Tuyl Christopher

Direct

Sell$103.5K
Aug 28, 26

Pande Atul

Direct

Sell$64.9K

1–10 of 64

Summary

Insiders reported 1 buys worth $350.00M and 63 sells worth $16.61M over the last 12 months. That adds up to net buying of $333.39M. Stout Jay S was the most active insider with 16 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Immunovant, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IMVT's management, answered from reported figures.

Who manages IMVT?

Immunovant, Inc. (IMVT) lists 10 active executives. The top listed executive is Eric Venker, Chief Executive Officer & Director.

Are IMVT insiders buying or selling?

Recent insider activity shows net buying of $747.77M.